Brean Murray Carret & Co. Starts Gentium (GENT) at Buy; Profitability Negates Downside Risk

April 4, 2012 8:03 AM EDT Send to a Friend
Get Alerts GENT Hot Sheet
Price: $8.87 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade GENT Now!
Brean Murray Carret & Co. initiates coverage on Gentium (NASDAQ: GENT) with a Buy. PT $16.00.

Analyst, Brian Skorney, said, "Gentium is already profitable from defibrotide sale even though the drug is not approved anywhere in the world. We believe the current valuation is justified by the current sales projectory, with significant upside potential (100%+) upon approval in the E.U., which we expect to occur next year."

For an analyst ratings summary and ratings history on Gentium click here. For more ratings news on Gentium click here.

Shares of Gentium closed at $8.93 yesterday, with a 52 week range of $5.31-$10.78.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment